nach oben

Drugs

Erschienen in:

01.09.2009 | Review Article

Interactions Between Herbal Medicines and Prescribed Drugs

An Updated Systematic Review

verfasst von: Professor Angelo A. Izzo, Professor Edzard Ernst

Erschienen in: Drugs | Ausgabe 13/2009

Einloggen, um Zugang zu erhalten

Abstract

The concomitant use of herbal medicines and pharmacotherapy is wide spread. We have reviewed the literature to determine the possible interactions between seven popular herbal medicines (ginkgo, St John’s wort, ginseng, garlic, echinacea, saw palmetto and kava) and conventional drugs. Literature searches were performed using MEDLINE, Cochrane Library and EMBASE and we identified 128 case reports or case series, and 80 clinical trials.

Clinical trials indicate that St John’s wort (Hypericum perforatum), via cytochrome P450 (CYP) and/or P-glycoprotein induction, reduces the plasma concentrations (and/or increases the clearance) of alprazolam, amitriptyline, atorvastatin, chlorzoxazone, ciclosporin, debrisoquine, digoxin, erythromycin, fexofenadine, gliclazide, imatinib, indinavir, irinotecan, ivabradine, mephenytoin, methadone, midazolam, nifedipine, omeprazole, oral contraceptives, quazepam, simvastatin, tacrolimus, talinolol, verapamil, voriconazole and warfarin. Case reports or case series suggest interactions of St John’s wort with adrenergic vasopressors, anaesthetics, bupropion, buspirone, ciclosporin, eletriptan, loperamide, nefazodone, nevirapine, oral contraceptives, paroxetine, phenprocoumon, prednisone, sertraline, tacrolimus, theophylline, tibolone, tryptophan, venlafaxine and warfarin. Ginkgo (Ginkgo biloba) decreases the plasma concentrations of omeprazole, ritonavir and tolbutamide. Clinical cases indicate interactions of ginkgo with antiepileptics, aspirin (acetylsalicylic acid), diuretics, ibuprofen, risperidone, rofecoxib, trazodone and warfarin. Ginseng (Panax ginseng) may interact with phenelzine and warfarin. Kava (Piper methysticum) increases the clearance of chlorzoxazone (a CYP2E1 substrate) and may interact with alprazolam, levodopa and paroxetine. Garlic (Allium sativum) interacts with chlorpropamide, fluindione, ritonavir and warfarin; it also reduces plasma concentrations of chlorzoxazone (a CYP2E1 probe). Echinacea might affect the clearance of caffeine (a CYP1A2 probe) and midazolam (a CYP3A4 probe). No interactions have been reported for saw palmetto (Serenoa repens.)

Numerous interactions between herbal medicines and conventional drugs have been documented. While the significance of many interactions is uncertain, several interactions, particularly those with St John’s wort, may have serious clinical consequences.

Nur mit Berechtigung zugänglich

Ernst E, Pittler MH, Wider B. The desktop guide to complementary and alternative medicine: an evidence-based approach. Philadelphia (PA): Mosby Elsevier, 2006

Ernst E, Pittler MH, Wider B, et al. Oxford handbook of complementary medicine. Oxford: Oxford University Press, 2008CrossRef

Capasso F, Gaginella TS, Grandolini G, et al. Phytotherapy: a quick reference to herbal medicine. Berlin: Springer-Verlag, 2003

Bent S. Herbal medicine in the United States: review of efficacy, safety, and regulation — grand rounds at University of California, San Francisco Medical Center. J Gen Intern Med 2008; 23: 854–9PubMedCrossRef

Zhou SF, Zhou ZW, Li CG, et al. Identification of drugs that interact with herbs in drug development. Drug Discov Today 2007; 12: 664–73PubMedCrossRef

Tomlinson B, Hu M, Lee VW. In vivo assessment of herb-drug interactions: possible utility of a pharmacogenetic approach? Mol Nutr Food Res 2008; 52: 799–809PubMedCrossRef

De Smet PA. Clinical risk management of herb-drug interactions. Br J Clin Pharmacol 2007; 63: 258–67PubMedCrossRef

Izzo AA. Herb-drug interactions: an overview of the clinical evidence. Fundam Clin Pharmacol 2005; 19: 1–16PubMedCrossRef

Butterweck V, Derendorf H. Potential of pharmacokinetic profiling for detecting herbal interactions with drugs. Clin Pharmacokinet 2008; 47(6): 383–97PubMedCrossRef

10.

Hu Z, Yang X, Ho PC, et al. Herb-drug interactions: a literature review. Drugs 2005; 65: 1239–82PubMedCrossRef

11.

Williamson EM. Drug interactions between herbal and prescription medicines. Drug Saf 2003; 26: 1075–92PubMedCrossRef

12.

Izzo AA, Borrelli F, Capasso R. Herbal medicine: the dangers of drug interaction. Trends Pharmacol Sci 2002; 23: 358–91PubMedCrossRef

13.

Yang GF, Huang X. Development of quantitative structure-activity relationships and its application in rational drug design. Curr Pharm Des 2006; 12: 4601–11PubMedCrossRef

14.

Zhou SF, Xue CC, Yu XQ, et al. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit 2007; 29: 687–710PubMedCrossRef

15.

Gardiner P, Phillips R, Shaughnessy AF. Herbal and dietary supplement: drug interactions in patients with chronic illnesses. Am Fam Physician 2008; 77: 73–8PubMed

16.

Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: a systematic review. Drugs 2001; 61: 2163–75PubMedCrossRef

17.

Williamson EM. Interactions between herbal and conventional medicines. Expert Opin Drug Saf 2005; 4: 355–78PubMedCrossRef

18.

Ernst E. Herb-drug interactions: an update. Perfusion 2003; 16: 175–94

19.

Ulbricht C, Chao W, Costa D, et al. Clinical evidence of herb-drug interactions: a systematic review by the natural standard research collaboration. Curr Drug Metab 2008; 9: 1062–119CrossRef

20.

Cranwell-Bruce L. Herb-drug interactions. Medsurg Nurs 2008; 17: 52–4PubMed

21.

Calapai G, Caputi AP. Herbal medicines: can we do without pharmacologist? Evid Based Complement Alternat Med 2007; 4: 41–3PubMedCrossRef

22.

Bush TM, Rayburn KS, Holloway SW, et al. Adverse interactions between herbal and dietary substances and prescription medications: a clinical survey. Alternat Ther Health Med 2007; 13: 30–5

23.

Kennedy J, Wang CC, Wu CH. Patient disclosure about herb and supplement use among adults in the US. Evid Based Complement Alternat Med 2008; 5: 451–6PubMedCrossRef

24.

Aslam M, Stockley IH. Interaction between curry ingredient (karela) and drug (chlorpropamide) [letter]. Lancet 1979; I: 607CrossRef

25.

Pathak A, Léger P, Bagheri H, et al. Garlic interaction with fluindione: a case report. Therapie 2003; 58: 380–1PubMedCrossRef

26.

Laroche M, Choudhuri S, Gallicano K, et al. Severe gastrointestinal toxicity with concomitant ingestion of ritonavir and garlic. Can J Infect Dis 1998; 9: 471P

27.

Sunter WH. Warfarin and garlic [letter]. PharmJ 1991;246: 772

28.

Kupiec T, Raj V. Fatal seizures due to potential herb-drug interactions with Ginkgo biloba. J Anal Toxicol 2005; 29: 755–8PubMed

29.

Rosenblatt M, Mindel J. Spontaneous hyphema associated with ingestion of Ginkgo biloba extract [letter]. N Engl J Med 1997; 336: 1108PubMedCrossRef

30.

Shaw D, Leon C, Kolev S, et al. Traditional remedies and food supplements: a 5-year toxicological study (1991–1995). Drug Saf 1997; 17: 342–56PubMedCrossRef

31.

Meisel C, Johne A, Roots I. Fatal intracerebral mass bleeding associated with Ginkgo biloba and ibuprofen [letter]. Atherosclerosis 2003; 167: 367PubMedCrossRef

32.

Lin YY, Chu SJ, Tsai SH. Association between priapism and concurrent use of risperidone and Ginkgo biloba. Mayo Clin Proc 2007; 82: 1289–90PubMedCrossRef

33.

Hoffman T. Ginkgo, vioxx and excessive bleeding: possible drug-herb interactions — case report [letter]. Hawaii Med J 2001; 60: 290PubMed

34.

Galluzzi S, Zanetti O, Binetti G, et al. Coma in a patient with Alzheimer’s disease taking low dose trazodone and gingko biloba. J Neurol Neurosurg Psychiatry 2000; 68: 679–80PubMedCrossRef

35.

Matthews Jr MK. Association of Ginkgo biloba with intracerebral hemorrhage. Neurology 1998; 50: 1933–4PubMedCrossRef

36.

Shader RI, Greenblatt DJ. Bees, ginseng and MAOIs revisited [letter]. J Clin Psychopharmacol 1988; 8: 235PubMed

37.

Jones BD, Runikis AM. Interaction of ginseng with phenelzine. J Clin Psychopharmacol 1987; 7: 201–2PubMedCrossRef

38.

Janetzky K, Morreale AP. Probable interaction between warfarin and ginseng. Am J Health Syst Pharm 1997; 54: 692–3PubMed

39.

Almeida JC, Grimsley EW. Coma from the health food store: interaction between kava and alprazolam. Ann Intern Med 1996; 125: 940–1PubMed

40.

Schelosky L, Raffauf C, Jendroska K, et al. Kava and dopamine antagonism. J Neurol Neurosurg Psychiatry 1995; 58: 639–40PubMedCrossRef

41.

Rubin D, McGovern B, Kopelman RI. Back to basics. Am J Med 2006; 119: 482–3PubMedCrossRef

42.

Irefin S, Sprung J. A possible cause of cardiovascular collapse during anesthesia: long-term use of St John’s wort. J Clin Anesth 2000; 12: 498–9PubMedCrossRef

43.

Crowe S, McKeating K. Delayed emergence and St John’s wort. Anesthesiology 2002; 96: 1025–7PubMedCrossRef

44.

Milton JC, Abdulla A. Prolonged oro-facial dystonia in a 58 year old female following therapy with bupropion and St John’s wort. Br J Clin Pharmacol 2007; 64: 717–8PubMedCrossRef

45.

Spinella M, Eaton LA. Hypomania induced by herbal and pharmaceutical psychotropic medicines following mild traumatic brain injury. Brain Inj 2002; 16: 359–67PubMedCrossRef

46.

Dannawi M. Possible serotonin syndrome after combination of buspirone and St John’s wort [letter]. J Psychopharmacol 2002; 16: 401PubMedCrossRef

47.

Bon S, Hartmann K, Kubn M. Johanniskraut: ein enzyminduktor? Schweitzer Apothekerzeitung 1999; 16: 535–6

48.

Breidenbach T, Kliem V, Burg M, et al. Profound drop of cyclosporin A whole blood trough levels caused by St John’s wort (Hypericum perforatum). Transplantation 2000; 69: 2229–30PubMedCrossRef

49.

Breidenbach T, Hoffmann MW, Becker T, et al. Drug interaction of St John’s wort with cyclosporin [letter]. Lancet 2000 May 27; 355(9218): 1912PubMedCrossRef

50.

Roots I, Johne A, Mauer A, et al. Arzneimittel interaktionen von hypericum-extract. Proceedings from the German Society of Pharmacology; 2000 Jun 16–17; Berlin

51.

Rey JM, Walter G. Hypericum perforatum (St John’s wort) in depression: pest or blessing? Med J Aust 1998; 169: 583–6PubMed

52.

Ruschitzka F, Meier PJ, Turina M, et al. Acute heart transplant rejection due to Saint John’s wort. Lancet 2000; 355: 548–9PubMedCrossRef

53.

Barone GW, Gurley BJ, Ketel BL, et al. Drug interaction between St John’s wort and cyclosporine. Ann Pharmacother 2000; 34: 1013–6PubMedCrossRef

54.

Mai I, Krüger H, Budde K, et al. Hazardous pharmacokinetic interaction of Saint John’s wort (Hypericum perforatum) with the immunosuppressant cyclosporin. Int J Clin Pharmacol Ther 2000; 38: 500–2PubMed

55.

Karliova M, Treichel U, Malagò M, et al. Interaction of Hypericum perforatum (St John’s wort) with cyclosporin A metabolism in a patient after liver transplantation. J Hepatol 2000; 33: 853–5PubMedCrossRef

56.

Mandelbaum A, Pertzborn F, Martin-Facklam M, et al. Unexplained decrease of cyclosporin trough levels in a compliant renal transplant patient. Nephrol Dial Transplant 2000; 15: 1473–4PubMedCrossRef

57.

Turton-Weeks SM, Barone GW, Gurley BJ, et al. St John’s wort: a hidden risk for transplant patients. Prog Transplant 2001; 11: 116–20PubMed

58.

Ahmed SM, Banner NR, Dubrey SW. Low cyclosporin-A level due to Saint-John’s-wort in heart transplant patients [letter]. J Heart Lung Transplant 2001; 20: 795PubMedCrossRef

59.

Beer AM, Ostermann T. St John’s wort: interaction with cyclosporine increases risk of rejection for the kidney transplant and raises daily cost of medication. Med Klin (Munich) 2001; 96: 480–3CrossRef

60.

Moschella C, Jaber BL. Interaction between cyclosporine and Hypericum perforatum (St John’s wort) after organ transplantation. Am J Kidney Dis 2001; 38: 1105–7PubMedCrossRef

61.

Alscher DM, Klotz U. Drug interaction of herbal tea containing St John’s wort with cyclosporine. Transpl Int 2003; 16: 543–4PubMedCrossRef

62.

Bonetto N, Santelli L, Battistin L, et al. Serotonin syndrome and rhabdomyolysis induced by concomitant use of triptans, fluoxetine and hypericum. Cephalalgia 2007; 27: 1421–3PubMedCrossRef

63.

Khawaja IS, Marotta RF, Lippmann S. Herbal medicines as a factor in delirium. Psychiatr Serv 1999; 50: 969–70PubMed

64.

Lantz MS, Buchalter E, Giambanco V. St John’s wort and antidepressant drug interactions in the elderly. J Geriatr Psychiatry Neurol 1999; 12: 7–10PubMedCrossRef

65.

de Maat MM, Hoetelmans RM, Matht RA, et al. Drug interaction between St John’s wort and nevirapine. AIDS 2001; 15: 420–1PubMedCrossRef

66.

Yue QY, Bergquist C, Gerdén B. Safety of St John’s wort (Hypericum perforatum). Lancet 2000; 355: 576–7PubMedCrossRef

67.

Schwarz UI, Büschel B, Kirch W. Unwanted pregnancy on self-medication with St John’s wort despite hormonal contraception. Br J Clin Pharmacol 2003; 55: 112–3PubMedCrossRef

68.

Gordon JB. SSRIs and St John’s wort: possible toxicity? [letter]. Am Fam Phys 1998; 57: 950

69.

Saraga M, Zullino DF. St John’s wort, corticosteroids, cocaine, alcohol … and a first manic episode [in French]. Praxis (Bern 1994) 2005; 94: 987–9CrossRef

70.

Barbenel DM, Yusufi B, O’Shea D, et al. Mania in a patient receiving testosterone replacement postorchidectomy taking St John’s wort and sertraline. J Psychopharmacol 2000; 14: 84–6PubMedCrossRef

71.

Bolley R, Zülke C, Kammerl M, et al. Tacrolimus-induced nephrotoxicity unmasked by induction of the CYP3A4 system with St John’s wort [letter]. Transplantation 2002; 73: 1009PubMedCrossRef

72.

Nebel A, Schneider BJ, Baker RK, et al. Potential metabolic interaction between St John’s wort and theophylline [letter]. Ann Pharmacother 1999; 33: 502PubMedCrossRef

73.

Etogo-Asse F, Boemer F, Sempoux C, et al. Acute hepatitis with prolonged cholestasis and disappearance of interlobular bile ducts following tibolone and Hypericum perforatum (St John’s wort): case of drug interaction? Acta Gastroenterol Belg 2008; 71: 36–8PubMed

74.

Bryant SM, Kolodchak J. Serotonin syndrome resulting from an herbal detox cocktail. Am J Emerg Med 2004; 22: 625–6PubMedCrossRef

75.

Prost N, Tichadou L, Rodor F, et al. St Johns wortvenlafaxine interaction. Presse Med 2000; 29: 1285–6PubMed

76.

Gorski JC, Huang SM, Pinto A, et al. The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther 2004; 75: 89–100PubMedCrossRef

77.

Gurley BJ, Gardner SF, Hubbard MA, et al. In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin Pharmacol Ther 2004; 76: 428–40PubMedCrossRef

78.

Gurley BJ, Swain A, Hubbard MA, et al. Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: effects of milk thistle, black cohosh, goldenseal, kava kava, St John’s wort, and echinacea. Mol Nutr Food Res 2008; 52: 755–63PubMedCrossRef

79.

Gurley BJ, Swain A, Williams DK, et al. Gauging the clinical significance of P-glycoprotein-mediated herbdrug interactions: comparative effects of St John’s wort, echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics. Mol Nutr Food Res 2008; 52: 772–9PubMedCrossRef

80.

Markowitz JS, Devane CL, Chavin KD, et al. Effects of garlic (Allium sativum L.) supplementation on cytochrome P450 2D6 and 3A4 activity in healthy volunteers. Clin Pharmacol Ther 2003; 74: 170–7PubMedCrossRef

81.

Gurley BJ, Gardner SF, Hubbard MA, et al. Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John’s wort, garlic oil, Panax ginseng and Ginkgo biloba. Drugs Aging 2005; 22: 525–39PubMedCrossRef

82.

Gurley BJ, Gardner SF, Hubbard MA, et al. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin Pharmacol Ther 2002; 72: 276–87PubMedCrossRef

83.

Jabbari A, Argani H, Ghorbanihaghjo A, et al. Comparison between swallowing and chewing of garlic on levels of serum lipids, cyclosporine, creatinine and lipid peroxidation in renal transplant recipients. Lipids Health Dis 2005; 4: 11PubMedCrossRef

84.

Cox MC, Low J, Lee J, et al. Influence of garlic (Allium sativum) on the pharmacokinetics of docetaxel. Clin Cancer Res 2006; 12: 4636–40PubMedCrossRef

85.

Gwilt PR, Lear CL, Tempero MA, et al. The effect of garlic extract on human metabolism of acetaminophen. Cancer Epidemiol Biomarkers Prev 1994; 3: 155–60PubMed

86.

Gallicano K, Foster B, Choudhri S. Effect of short-term administration of garlic supplements on single-dose ritonavir pharmacokinetics in healthy volunteers. Br J Clin Pharmacol 2003; 55: 199–202PubMedCrossRef

87.

Piscitelli SC, Burstein AH, Welden N, et al. The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis 2002; 34: 234–8PubMedCrossRef

88.

Macan H, Uykimpang R, Alconcel M, et al. Aged garlic extract may be safe for patients on warfarin therapy. J Nutr 2006; 136: 793S–5SPubMed

89.

Mohammed Abdul MI, Jiang X, Williams KM, et al. Pharmacodynamic interaction of warfarin with cranberry but not with garlic in healthy subjects. Br J Pharmacol 2008; 154: 1691–700PubMedCrossRef

90.

Gardner CD, Zehnder JL, Rigby AJ, et al. Effect of Ginkgo biloba (EGb 761) and aspirin on platelet aggregation and platelet function analysis among older adults at risk of cardiovascular disease: a randomized clinical trial. Blood Coagul Fibrinolysis 2007; 18: 787–93PubMedCrossRef

91.

Markowitz JS, Donovan JL, Lindsay DeVane C, et al. Multiple-dose administration of Ginkgo biloba did not affect cytochrome P-450 2D6 or 3A4 activity in normal volunteers. J Clin Psychopharmacol 2003; 23: 576–81PubMedCrossRef

92.

Aruna D, Naidu MU. Pharmacodynamic interaction studies of Ginkgo biloba with cilostazol and clopidogrel in healthy human subjects. Br J Clin Pharmacol 2007; 63: 333–8PubMedCrossRef

93.

Mohutsky MA, Anderson GD, Miller JW, et al. Ginkgo biloba: evaluation of CYP2C9 drug interactions in vitro and in vivo. Am J Ther 2006; 13: 24–31PubMedCrossRef

94.

Mauro VF, Mauro LS, Kleshinski JF, et al. Impact of Ginkgo biloba on the pharmacokinetics of digoxin. Am J Ther 2003; 10: 247–51PubMedCrossRef

95.

Robertson SM, Davey RT, Voell J, et al. Effect of Ginkgo biloba extract on lopinavir, midazolam and fexofenadine pharmacokinetics in healthy subjects. Curr Med Res Opin 2008; 24: 591–9PubMedCrossRef

96.

Greenblatt DJ, von Moltke LL, Luo Y, et al. Ginkgo biloba does not alter clearance of flurbiprofen, a cytochrome P450-2C9 substrate. J Clin Pharmacol 2006; 46: 214–21PubMedCrossRef

97.

Uchida S, Yamada H, Li XD, et al. Effects of Ginkgo biloba extract on pharmacokinetics and pharmacodynamics of tolbutamide and midazolam in healthy volunteers. J Clin Pharmacol 2006; 46: 1290–8PubMedCrossRef

98.

Yoshioka M, Ohnishi N, Koishi T, et al. Studies on interactions between functional foods or dietary supplements and medicines. IV: effects of Ginkgo biloba leaf extract on the pharmacokinetics and pharmacodynamics of nifedipine in healthy volunteers. Biol Pharm Bull 2004; 27: 2006–9

99.

Yin OQ, Tomlinson B, Waye MM, et al. Pharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole. Pharmacogenetics 2004; 14: 841–50PubMedCrossRef

100.

Duche JC, Barre J, Guinot P, et al. Effect of Ginkgo biloba extract on microsomal enzyme induction. Int J Clin Pharmacol Res 1989; 9: 165–8PubMed

101.

Jiang X, Williams KM, Liauw WS, et al. Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol 2005; 59: 425–32PubMedCrossRef

102.

Engelsen J, Nielsen JD, Winther K. Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in stable, long-term warfarin treated outpatients: a randomised, double blind, placebo-crossover trial. Thromb Haemost 2002; 87: 1075–6PubMed

103.

Jiang X, Williams KM, Liauw WS, et al. Effect of St John’s wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol 2004; 57: 592–9PubMedCrossRef

104.

Lee SH, Ahn YM, Ahn SY, et al. Interaction between warfarin and Panax ginseng in ischemic stroke patients. J Altern Complement Med 2008; 14: 715–21PubMedCrossRef

105.

Gurley BJ, Swain A, Barone GW, et al. Effect of goldenseal (Hydrastis canadensis) and kava kava (Piper methysticum) supplementation on digoxin pharmacokinetics in humans. Drug Metab Dispos 2007; 35: 240–5PubMedCrossRef

106.

Gurley BJ, Swain A, Hubbard MA, et al. Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo. Clin Pharmacol Ther 2008; 83: 61–9PubMedCrossRef

107.

Gurley BJ, Gardner SF, Hubbard MA, et al. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther 2005; 77: 415–26PubMedCrossRef

108.

Markowitz JS, Donovan JL, Devane CL, et al. Multiple doses of saw palmetto (Serenoa repens) did not alter cytochrome P450 2D6 and 3A4 activity in normal volunteers. Clin Pharmacol Ther 2003; 74: 536–42PubMedCrossRef

109.

Markowitz JS, DeVane CL, Boulton DW, et al. Effect of St John’s wort (Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers. Life Sci 2000; 66: PL133–9PubMedCrossRef

110.

Markowitz JS, Donovan JL, DeVane CL, et al. Effect of St John’s wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 2003; 290: 1500–4PubMedCrossRef

111.

Arold G, Donath F, Maurer A, et al. No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St John’s wort extract. Planta Med 2005; 71: 331–7PubMedCrossRef

112.

Johne A, Schmider J, Brockmöller J, et al. Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St John’s wort (Hypericum perforatum). J Clin Psychopharmacol 2002; 22: 46–54PubMedCrossRef

113.

Andrén L, Andreasson A, Eggertsen R. Interaction between a commercially available St John’s wort product (Movina) and atorvastatin in patients with hypercholesterolemia. Eur J Clin Pharmacol 2007; 63(10): 913–6PubMedCrossRef

114.

Burstein AH, Horton RL, Dunn T, et al. Lack of effect of St John’s wort on carbamazepine pharmacokinetics in healthy volunteers. Clin Pharmacol Ther 2000; 68: 605–12PubMedCrossRef

115.

Wang Z, Gorski JC, Hamman MA, et al. The effects of St John’s wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 2001; 70: 317–26PubMed

116.

Wang LS, Zhu B, Abd El-Aty AM, et al. The influence of St John’s wort on CYP2C19 activity with respect to genotype. J Clin Pharmacol 2004 Jun; 44(6): 577–81PubMedCrossRef

117.

Wenk M, Todesco L, Krähenbühl S. Effect of St John’s wort on the activities of CYP1A2, CYP3A4, CYP2D6, Nacetyltransferase 2, and xanthine oxidase in healthy males and females. Br J Clin Pharmacol 2004; 57: 495–9PubMedCrossRef

118.

Dresser GK, Schwarz UI, Wilkinson GR, et al. Coordinate induction of both cytochrome P4503A and MDR1 by St John’s wort in healthy subjects. Clin Pharmacol Ther 2003; 73: 41–50PubMedCrossRef

119.

Mai I, Bauer S, Perloff ES, et al. Hyperforin content determines the magnitude of the St John’s wort-cyclosporine drug interaction. Clin Pharmacol Ther 2004; 76: 330–40PubMedCrossRef

120.

Roby CA, Dryer DA, Burstein AH. St John’s wort: effect on CYP2D6 activity using dextromethorphan-dextrorphan ratios. J Clin Psychopharmacol 2001; 21: 530–2PubMedCrossRef

121.

Johne A, Brockmöller J, Bauer S, et al. Pharmacokinetic interaction of digoxin with an herbal extract from St John’s wort (Hypericum perforatum). Clin Pharmacol Ther 1999; 66: 338–45PubMedCrossRef

122.

Mueller SC, Uehleke B, Woehling H, et al. Effect of St John’s wort dose and preparations on the pharmacokinetics of digoxin. Clin Pharmacol Ther 2004; 75: 546–57PubMedCrossRef

123.

Dürr D, Stieger B, Kullak-Ublick GA, et al. St John’s wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 2000; 68: 598–604PubMedCrossRef

124.

Wang Z, Hamman MA, Huang SM, et al. Effect of St John’s wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther 2002; 71: 414–20PubMedCrossRef

125.

Xie R, Tan LH, Polasek EC, et al. CYP3A and P-glycoprotein activity induction with St John’s wort in healthy volunteers from 6 ethnic populations. J Clin Pharmacol 2005; 45: 352–6PubMedCrossRef

126.

Xu H, Williams KM, Liauw WS, et al. Effects of St John’s wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide. Br J Pharmacol 2008; 153: 1579–86PubMedCrossRef

127.

Frye RF, Fitzgerald SM, Lagattuta TF, et al. Effect of St John’s wort on imatinib mesylate pharmacokinetics. Clin Pharmacol Ther 2004; 76: 323–9PubMedCrossRef

128.

Smith P, Bullock JM, Booker BM, et al. The influence of St John’s wort on the pharmacokinetics and protein binding of imatinib mesylate. Pharmacotherapy 2004; 24: 1508–14PubMedCrossRef

129.

Piscitelli SC, Burstein AH, Chaitt D, et al. Indinavir concentrations and St John’s wort. Lancet 2000; 355: 547–8PubMedCrossRef

130.

Mathijssen RH, Verweij J, de Bruijn P, et al. Effects of St John’s wort on irinotecan metabolism. J Natl Cancer Inst 2002; 94: 1247–9PubMedCrossRef

131.

Portolés A, Terleira A, Calvo A, et al. Effects of Hypericum perforatum on ivabradine pharmacokinetics in healthy volunteers: an open-label, pharmacokinetic interaction clinical trial. J Clin Pharmacol 2006; 46: 1188–94PubMedCrossRef

132.

Eich-Höchli D, Oppliger R, Golay KP, et al. Methadone maintenance treatment and St John’s wort: a case report. Pharmacopsychiatry 2003; 36: 35–7PubMedCrossRef

133.

Mai I, Störmer E, Bauer S, et al. Impact of St John’s wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients. Nephrol Dial Transplant 2003; 18: 819–22PubMedCrossRef

134.

Hall SD, Wang Z, Huang SM, et al. The interaction between St John’s wort and an oral contraceptive. Clin Pharmacol Ther 2003; 74: 525–35PubMedCrossRef

135.

Mueller SC, Majcher-Peszynska J, Uehleke B, et al. The extent of induction of CYP3A by St John’s wort varies among products and is linked to hyperforin dose. Eur J Clin Pharmacol 2006; 62: 29–36PubMedCrossRef

136.

Mueller SC, Majcher-Peszynska J, Mundkowski RG, et al. No clinically relevant CYP3A induction after St John’s wort with low hyperforin content in healthy volunteers. Eur J Clin Pharmacol 2009; 65: 81–7PubMedCrossRef

137.

Imai H, Kotegawa T, Tsutsumi K, et al. The recovery time-course of CYP3A after induction by St John’s wort administration. Br J Clin Pharmacol 2008; 65: 701–7PubMedCrossRef

138.

L’homme RF, Dijkema T, van der Ven AJ, et al. Brief report: enzyme inducers reduce elimination half-life after a single dose of nevirapine in healthy women. J Acquir Immune Defic Syndr 2006; 43: 193–6PubMedCrossRef

139.

Wang XD, Li JL, Su QB, et al. Impact of the haplotypes of the human pregnane X receptor gene on the basal and St John’s wort-induced activity of cytochrome P450 3A4 enzyme. Br J Clin Pharmacol 2009; 67: 255–61PubMedCrossRef

140.

Wang LS, Zhou G, Zhu B, et al. St John’s wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole. Clin Pharmacol Ther 2004; 75: 191–7PubMedCrossRef

141.

Pfrunder A, Schiesser M, Gerber S, et al. Interaction of St John’s wort with low-dose oral contraceptive therapy: a randomized controlled trial. Br J Clin Pharmacol 2003; 56: 683–90PubMedCrossRef

142.

Murphy PA, Kern SE, Stanczyk FZ, et al. Interaction of St John’s wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding. Contraception 2005; 71: 402–8PubMedCrossRef

143.

Will-Shahab L, Bauer S, Kunter U, et al. St John’s wort extract (Ze 117) does not alter the pharmacokinetics of a low-dose oral contraceptive. Eur J Clin Pharmacol 2009; 65: 287–94PubMedCrossRef

144.

Donath F, Roots I, Langheinrich M, et al. Interaction of St John’s wort extract with phenprocoumon [abstract]. Eur J Clin Pharmacol 1999; 55: A22

145.

Sugimoto K, Ohmori M, Tsuruoka S, et al. Different effects of St John’s wort on the pharmacokinetics of simvastatin and pravastatin. Clin Pharmacol Ther 2001; 70: 518–24PubMedCrossRef

146.

Bell EC, Ravis WR, Chan HM, et al. Lack of pharmacokinetic interaction between St John’s wort and prednisone. Ann Pharmacother 2007; 41: 1819–24PubMedCrossRef

147.

Kawaguchi A, Ohmori M, Tsuruoka S, et al. Drug interaction between St John’s wort and quazepam. Br J Clin Pharmacol 2004; 58: 403–10PubMedCrossRef

148.

Hebert MF, Park JM, Chen YL, et al. Effects of St John’s wort (Hypericum perforatum) on tacrolimus pharmacokinetics in healthy volunteers. J Clin Pharmacol 2004; 44: 89–94PubMedCrossRef

149.

Schwarz UI, Hanso H, Oertel R, et al. Induction of intestinal P-glycoprotein by St John’s wort reduces the oral bioavailability of talinolol. Clin Pharmacol Ther 2007; 81: 669–78PubMedCrossRef

150.

Morimoto T, Kotegawa T, Tsutsumi K, et al. Effect of St John’s wort on the pharmacokinetics of theophylline in healthy volunteers. J Clin Pharmacol 2004; 44: 95–101PubMedCrossRef

151.

Tannergren C, Engman H, Knutson L, et al. St John’s wort decreases the bioavailability of R- and S-verapamil through induction of the first-pass metabolism. Clin Pharmacol Ther 2004; 75: 298–309PubMedCrossRef

152.

Rengelshausen J, Banfield M, Riedel KD, et al. Opposite effects of short-term and long-term St John’s wort intake on voriconazole pharmacokinetics. Clin Pharmacol Ther 2005; 78: 25–33PubMedCrossRef

153.

Smith PF, Bullock JM, Booker BM, et al. Induction of imatinib metabolism by hypericum perforatum. Blood 2004; 104: 1229–30PubMedCrossRef

154.

Freeman C, Spelman K. A critical evaluation of drug interactions with Echinacea spp. Mol Nutr Food Res 2008; 52: 789–98PubMedCrossRef

155.

Borrelli F, Capasso R, Izzo AA. Garlic (Allium sativum L.): adverse effects and drug interactions in humans. Mol Nutr Food Res 2007; 51: 1386–97PubMedCrossRef

156.

Engdal S, Nilsen OG. Inhibition of P-glycoprotein in Caco-2 cells: effects of herbal remedies frequently used by cancer patients. Xenobiotica 2008; 38: 559–73PubMedCrossRef

157.

Saw JT, Bahari MB, Ang HH, et al. Potential drug-herb interaction with antiplatelet/anticoagulant drugs. Ther Clin Pract 2006; 12: 236–41CrossRef

158.

Fugh-Berman A, Ernst E. Herb-drug interactions: review and assessment of report reliability. Br J Clin Pharmacol 2001; 52: 587–95PubMedCrossRef

159.

Bone KM. Potential interaction of Ginkgo biloba leaf with antiplatelet or anticoagulant drugs: what is the evidence? Mol Nutr Food Res 2008; 52: 764–71PubMedCrossRef

160.

Fessenden JM, Wittenborn W, Clarke L. Gingko biloba: a case report of herbal medicine and bleeding postoperatively from a laparoscopic cholecystectomy. Am Surg 2001; 67: 33–5PubMed

161.

Jayasekera N, Moghal A, Kashif F, et al. Herbal medicines and postoperative haemorrhage. Anaesthesia 2005; 60: 725–6PubMedCrossRef

162.

Ernst E, Canter PH, Coon JT. Does Ginkgo biloba increase the risk of bleeding? A systemic review of case reports. Perfusion 2005; 18: 52–6

163.

Savović J, Wider B, Ernst E. Effects of Ginkgo biloba on blood coagulation parameters: a systematic review of randomised clinical trials. Evid Based Integrative Med 2005; 2: 167–76CrossRef

164.

Kiefer D, Pantuso T. Panax ginseng. Am Fam Physician 2003; 68: 1539–42PubMed

165.

Beckert BW, Concannon MJ, Henry SL, et al. The effect of herbal medicines on platelet function: an in vivo experiment and review of the literature. Plast Reconstr Surg 2007; 120: 2044–50PubMedCrossRef

166.

Yuan CS, Wei G, Dey L, et al. Brief communication: American ginseng reduces warfarin’s effect in healthy patients — a randomized, controlled trial. Ann Intern Med 2004; 141: 23–7PubMed

167.

Shader RI, Greenblatt DJ. Phenelzine and the dream machine: ramblings and reflections [letter]. J Clin Psychopharmacol 1985; 5: 65PubMedCrossRef

168.

Avins AL, Bent S, Staccone S, et al. A detailed safety assessment of a saw palmetto extract. Complement Ther Med 2008; 16: 147–54PubMedCrossRef

169.

Agbabiaka TB, Pittler MH, Wider B, et al. Serenoa repens (saw palmetto): a systematic review of adverse events. Drug Saf 2009; 32(8): 637–47PubMedCrossRef

170.

Linde K, Berner MM, Kriston L. St John’s wort for major depression. Cochrane Database Syst Rev 2008; (4): CD000448

171.

Rahimi R, Nikfar S, Abdollahi M. Efficacy and tolerability of Hypericum perforatum in major depressive disorder in comparison with selective serotonin reuptake inhibitors: a meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 118–27PubMedCrossRef

172.

Knüppel L, Linde K. Adverse effects of St John’s wort: a systematic review. J Clin Psychiatry 2004; 65: 1470–9PubMedCrossRef

173.

Di Carlo G, Borrelli F, Ernst E, et al. St John’s wort: Prozac from the plant kingdom. Trends Pharmacol Sci 2001; 22: 292–7PubMedCrossRef

174.

Izzo AA. Drug interactions with St John’s wort (Hypericum perforatum): a review of the clinical evidence. Int J Clin Pharmacol Ther 2004; 42: 139–48PubMed

175.

Mannel M. Drug interactions with St John’s wort: mechanisms and clinical implications. Drug Saf 2004; 27: 773–97PubMedCrossRef

176.

Di YM, Li CG, Xue CC, et al. Clinical drugs that interact with St John’s wort and implication in drug development. Curr Pharm Des 2008; 14: 1723–42PubMedCrossRef

177.

Mills E, Montori VM, Wu P, et al. Interaction of St John’s wort with conventional drugs: systematic review of clinical trials. BMJ 2004; 329: 27–30PubMedCrossRef

178.

Madabushi R, Frank B, Drewelow B, et al. Hyperforin in St John’s wort drug interactions. Eur J Clin Pharmacol 2006; 62: 225–33PubMedCrossRef

179.

Bressler R. Herb-drug interactions: St John’s wort and prescription medications. Geriatrics 2005; 60: 21–3PubMed

180.

Ernst E. St John’s wort supplements endanger the success of organ transplantation. Arch Surg 2002; 137: 316–9PubMedCrossRef

181.

Murphy PA. St John’s wort and oral contraceptives: reasons for concern? J Midwifery Womens Health 2002; 47: 447–50PubMedCrossRef

182.

Izzo AA, Di Carlo G, Borrelli F, et al. Cardiovascular pharmacotherapy and herbal medicines: the risk of drug interaction. Int J Cardiol 2005; 98: 1–14PubMedCrossRef

183.

Van den Bout-van den Beukel CJ, Koopmans PP, van der Ven AJ, et al. Possible drug-metabolism interactions of medicinal herbs with antiretroviral agents. Drug Metab Rev 2006; 38: 477–514PubMedCrossRef

184.

Erickson DA, Mather G, Trager WF, et al. Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos 1999; 27: 1488–95PubMed

185.

Meijerman I, Beijnen JH, Schellens JH. Herb-drug interactions in oncology: focus on mechanisms of induction. Oncologist 2006; 11: 742–52PubMedCrossRef

186.

Werneke U, Turner T, Priebe S. Complementary medicines in psychiatry: review of effectiveness and safety. Br J Psychiatry 2006; 188: 109–21PubMedCrossRef

187.

Ernst E, Rand JI, Barnes J, et al. Adverse effects profile of the herbal antidepressant St John’s wort (Hypericum perforatum L.). Eur J Clin Pharmacol 1998; 54(8): 589–94PubMedCrossRef

188.

Johne A, Perloff ES, Bauer S, et al. Impact of cytochrome P-450 inhibition by cimetidine and induction by carbamazepine on the kinetics of hypericin and pseudohypericin in healthy volunteers. Eur J Clin Pharmacol 2004; 60: 617–22PubMedCrossRef

189.

Ang-Lee MK, Moss J, Yuan CS. Herbal medicines and perioperative care. JAMA 2001; 286: 208–16PubMedCrossRef

Titel: Interactions Between Herbal Medicines and Prescribed Drugs
An Updated Systematic Review
verfasst von: Professor Angelo A. Izzo
Professor Edzard Ernst
Publikationsdatum: 01.09.2009
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 13/2009
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.2165/11317010-000000000-00000

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 13/2009

Management of Ascites

Aprepitant

Salmeterol/Fluticasone Propionate

Rivaroxaban

Advanced-Stage Follicular Lymphoma in the Rituximab Era

Fixed-Dose Combinations as Initial Therapy for Hypertension